When stratified into the three groups, loss of ATRX expression (n = 44) retained its role as a negative prognostic marker for malignant progression only among astrocytoma, IDH mutant (p = 0.029). The gene discussed is ATRX; the disease is astrocytoma (excluding glioblastoma).